Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Ovarian Neoplasms 5Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Glioblastoma 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uveal Melanoma 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hypertension 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Mucinous Adenocarcinoma × cediranib × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡